AIS Healthcare

AIS Healthcare

AIS Healthcare was founded at an undisclosed date, with an executive team that includes Simon Castellanos, Pam Carter, and Julia Doucette among 11 named leaders. Its ownership structure is not publicly disclosed, and the firm does not market itself as a family office or investment vehicle. The company operates from a Dallas headquarters with additional infusion center locations across the country. AIS Healthcare focuses on two divisions: Advanced Infusion Care (AIC) provides in-home immunoglobulin and Alpha-1 therapy along with infusion centers; Targeted Drug Delivery (TDD) operates two state-of-the-art 503A compounding pharmacies that produce patient-specific medications for implanted intrathecal pumps. The firm employs over 300 nurses nationwide and is dually accredited by URAC and the Accreditation Commission for Health Care. In May 2022, AIS Healthcare exited the ophthalmology market, discontinuing its NovoTears and OPDrops products to concentrate on complex chronic conditions. The scale of AIS Healthcare's operations is notable for a single brand: it manages a national nursing network, multiple infusion centers, and two redundant compounding pharmacies. Recent expansions include a new infusion center in Louisville, KY, and another in Atlanta, GA. The firm also provides financial assistance programs for patients in both its TDD and AIC divisions. AIS Healthcare distinguishes itself structurally by integrating pharmacy compounding, infusion nursing, and clinic services within one organization, rather than fragmenting these functions across separate providers. This vertical integration — rare in the infusion space — allows the firm to control medication quality from compounding through administration.